New hope for Tough-to-Treat leukemia: phase 3 trial pits rocbrutinib against pirtobrutinib
NCT ID NCT07342478
First seen Jan 16, 2026 · Last updated May 09, 2026 · Updated 13 times
Summary
This study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. About 306 adults will take one of the two pills daily to see which works better at controlling the cancer. The goal is to find a more effective option for patients who have already tried a BTK inhibitor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OSU Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
Optum Medical Group (Rhodes) P.C.
RECRUITINGLas Vegas, Nevada, 89102, United States
-
UPMC Hillman Cancer Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.